Straws are discrete research notes that relate to a particular aspect of the company. Grouped under #hashtags, they are ranked by votes.
A good Straw offers a clear and concise perspective on the company and its prospects.
Please visit the forums tab for general discussion.
Healthcare tech provider and Strawman Community favourite $AHC posted their 1H FY26 yesterday. I've been watching this one ever since it was put on my radarscreen by several of the most illustrious StrawPeople, and have in recent weeks opened an initial position following its fall below my "buy" price of $0.35. (RL 4%, although I'm yet to add on SM).
As this is my first coverage of $AHC, my reason for lurking for so long is that I wanted to get a better feeling for how it's M&A strategy is playing out, as I tend to be reluctant when firm's use M&A because i) it muddies the waters of the historical numbers, so I can't see the underlying "economic engine" and ii) well, because I don't like M&A unless I get confident that management know what they are doing. Other than that $AHC is in my sweetspot, combining healthcare and tech, and so I've taken an initial bite.
@MangroveJack has already given the headlines, however, because the impressive headline result includes organic and inorganic contributions, I've decided to have a go at pulling things apart in some future detail.
In a break from my usual structure, I drop 3 charts - to give a sense of half-on-half variations and overall trends. Then I'll record my analysis.
My valuation will follow in a few days, however, from my work so far, its looking broadly in line with @Hogajo ($0.45) and @Wini ($0.50) at my p50%, although my range is a bit wider.
As I said, while I have been following this one for a few years, this is my first write up, so I'm very keen for any feedback from those StrawPeople who have a better understanding of this microcap.



Summary
Austco Healthcare delivered a record performance in 1H FY26, combining acquisitions and organic growth to drive revenue up 30.7% to $48.2 million and net profit after tax up 61.7% to $4.7 million.
The company look like it might be demonstrating some operating leverage, expanding EBITDA margins to 17.1% while holding %GM within the range of the last few years.
The result gives an initial positive indication of its strategy to vertically integrate ANZ reseller businesses without diluting profitability.
With a debt-free balance sheet holding $15.2 million in cash and a substantial order backlog of $47.2 million, Austco has solidified its financial position while maintaining strong visibility on future earnings.
As fas as I can discern, acquisitions are currently the primary engine of this growth, and it will be important to see what the organic "engine" looks like from here over the coming periods.
Today's result seems to reduce my view of the risk that low-margin installation revenue would dilute Group quality; instead, Austco seems to be capture more of the value chain margin.
With the UCR flattening, future growth will likely require either new M&A targets in other regions (North America/Europe) or a re-acceleration of pure organic software sales to drive the next leg of expansion. Personally, I hope we get to see some of the latter first, although, the results are encouraging, indicating that management are adept at identifying the right acquisitions, keeping them appropriately sized and then executing well.
My Detailed Assessment
1. Revenue Growth: Inorganic Drivers dominate
Revenue rose 30.7% to $48.2 million.
This follows a 40% jump in FY25 full-year revenue. The growth trajectory remains steep, but the composition has shifted.
Organic vs. Inorganic: While the company cites "continued organic growth," particularly in North America, the primary driver appears to be the full-period contribution of recent acquisitions (Teknocorp, Amentco, and G&S Technologies).
2. Margins and Operating Leverage: The Key Success Story
The most critical positive in this result is the expansion of margins despite the integration of typically lower-margin reseller businesses.
3. Earnings Quality and Cash Flow
4. Forward Visibility
Unfilled Contracted Revenue (UCR): Stood at $47.2million. While substantial, this has essentially plateaued since August 2024 ($50.3 million) and June 2025 ($53.8 million). A flat or slightly declining UCR in a high-growth environment suggests that while the company is executing delivery (converting order book to revenue) efficiently, the rate of new organic wins may be stabilizing rather than accelerating. The order book is being consumed as fast as it is being replenished. This is something that will be important to monitor over the next coupld of 6-month periods.
Overall, a nice result. And although the market agreed with the SP up 18+% today, this movement has to be considered in the context of the pullback over the last 3-4 months.
Disc: Held (RL 4%)
Austco results out after the bell, looks good:
• Revenue from customers up 30.7% to $48.2 million
• EBITDA margin increased from 14.0% to 17.1%
• EBITDA grew 60.1% to $8.3 million
• Net Profit Before Tax up 62.1% to $6.3 million
• Unfilled Contracted Revenue of $47.2 million provides visibility into future earnings
• Debt-free with $15.2 million cash on balance sheet
Things to note, this is the first time the order book dropped, but still very high, and sales are lumpy and after it growing so much I was expecting this to move around.
Asia had some timing issues and Europe was flat on revenue.
Austco released a trading update today to coincide with their AGM later this morning. Overall impression is it was what you would want to see, which is to say, solid. They didn't break down the organic/inorganic split, which would have been nice, but did reconfirm targeted 10-14% organic growth for FY26. Highlights included:
• Revenue of $23.2 million, up 51% on the pcp, which includes both organic and inorganic growth.
• EBITDA of $4.2 million, representing 18.1% EBITDA margin, up from 16.0% at FY25 year-end.
• Order book of $54.6 million at 23 October 2025.
Here's how the order book has tracked over the past six years:

Overall it continues to deliver at or above what I need it to in order to justify continuing to hold. I've been lightening some positions that have gotten a bit frothy in recent months but Austco is not one of them.
[Held]
Great trading update by Austco, continues to perform

Good to see some actual Performance Rights with Hurdles. Not common in the shares I hold down in this part of the market cap world.

AHC closed 2.5c up on Friday to break through 40c and close at 41c. It had been threatening to do so for a while. Might this indicate a positive update will be released very soon?
Sure, it's a growth-by-acquisition story, but at least they are acquiring into an industry with structural growth tailwinds.
Net Profit After Tax lower: $5,933Mill (16.2%)
Net Debt/ Equity is ok so has liquidity here .. We looking for the these acquisitions to be integrated, sustainable.
https://hotcopper.com.au/threads/ann-appendix-4e-fy25-financial-statements.8731195/




Unfilled Contracted Revenue Recent large contract wins in North America and growth in most other regions across the group have contributed to the continued growth of Austco’s Unfilled Contracted Revenue (UCR). Our UCR book now stands at $53.8 million at 13 August 2025. This includes a net $6.3 million from the recently acquired G&S, being their UCR less orders they had open with Austco NZ.
Cash and Working Capital Position Cash on hand was $14.5m at 30 June 2025, up from $13.6 million at June 2024. Cash generated from operating activities of $13.48 million reflected underlying profitability and allowed for the investment into further businesses (G&S acquired in May 2025) without the need for debt or raising capital. Despite working capital increasing as a result of acquiring G&S, the Group is well placed to fund future contingent consideration obligations without the need for liquidity events, if it chooses to do so.

Return (inc div) 1yr: 71.43% 3yr: 50.53% pa 5yr: 38.36% pa

The likely outlook for AHC - no company-issued forward guidance!
I couldn’t find any company-issued, forward-looking guidance for FY 2026 from Austco Healthcare (ASX: AHC)—no specific projections for EPS growth, revenue targets, or contract estimates are disclosed publicly at this time.
Austco has provided detailed FY 2025 guidance in its ASX announcement dated 23 July 2025:
These figures provide insight into Austco’s near-term expectations but stop short of detailing FY 2026.
YearEPS GrowthRevenue GrowthContracts (Pipeline)FY 2025Not disclosedGuided: +37–41% (AUD 80–82 m)Pipeline: AUD 55.8 mFY 2026———Analyst Avg.~18.9% p.a.~14.3% p.a. (multi-year)—
If you're seeking FY 2026 guidance, you may want to monitor these channels:
Austco today announcing the acquisition of NZ-based call system solutions provider and Austco reseller, G&S Technologies. I don't know about others but I find it very difficult to play armchair quarterback on acquisitions. There are just too many factors, like working capital pegs and balance sheet health, that are completely unknown unless you're in the tent. However, what we can say based on what's available to us:

Only slight quibble is that they didn't take the opportunity to update on the order book but I'm nit picking.
[Held]
Austco provided a short update on the first quarter of the year. The update was light on details, with no mention of profit or cashflow numbers.
This could be interpreted negatively, but I’m not certain that’s what this means. I think it's more likely that they are using their privilege to not have to report these.
Whilst microcap Jesus gave them some grief on Twitter for reporting the order book in a very selective way which I agree with, it feels like the market is missing that growth with acquisitions is coming in at 90%.
If we use the same profit margin as last year, which was actually quite high at 13%, my back of the napkin math is that they may end the year on a PE of around 8-10.
If the organic growth can be maintained at 15%, then the fair PE should be somewhere around 15. This implies fair value on the stock somewhere around $0.45.
@LifeCapital and @BendigoInvesto covered this, so I won't back over what they've written. Except to say that I was scratching my head at this result. The numbers just looked too good, and I couldn't get them anywhere near to adding up until I re-read almost to the bottom of their trading update:

Talk about burying the lead - a 5.6% increase in GM is huge! Much higher than anything they've done for at least 10 years. What is that? Is that Technocorp? I'd thought of Technocorp as strategically important, but of lower quality than the existing business. That isn't borne out by the numbers though:

So Teknocorp appears to be holding its own and then some. But the underlying business appears to have had a standout quarter as well. While I thought the 1H numbers were fair-to-good, I had expected a lot more given the growth in order book and commentary around impacts of COVID impacts easing. Q3 appears to have made up for that.
It's just as dangerous to extrapolate a good quarter as it is a bad one, but I'll do it anyway cause I'm a slow learner. Although they disclose NPAT, I'll focus on EBITDA because their tax is all over the shop. They are run-rating at almost $10 million EBITDA, which is an EV/EBITDA ratio under 6. Add a record order book and I'm a happy holder.

All important for small caps.
Share count @ June 2020: 284 188 951
Share count @ December 2023: 290 790 167
Share count growth: 0.8% pa.
Austco has come out with a roadshow presentation today, with lots of funky graphs and "buy me" arguments. Not a lot new, although they did disclose sales orders were up again from last month's record high to $37.2m - so they're filling the funnel faster than they can drain it. (Ignore the 'Revenue from customers' tag - revenue it ain't).

Austco is one of my more comfortable holdings. They disclose often enough to make you feel wanted, without getting all over-promotional. When they make investments in product or people they set realistic expectations about how long it will take to get a payback from the investment. They certainly appear to be in that zone of getting a return of previous investment right now though.
If I were being hyper-critical I'd say the CEO is very well compensated for a company of this size. However, Clayton appears to be getting the job done so I'll not quibble while that remains the case. It's arguably not a screaming bargain but if they keep growing at the rate they are it will look cheap soon enough. Happy to hold.
Decent revenue growth, but I was expecting a higher NPAT result. This year should be strong though for the following reasons -
So putting this all together, I would expect Sales to come in at around $52m for FY24 up $10m on FY23. Adding back the saving on R&D of $900k, I would guess that AHC could achieve at least $4m in NPAT. Working on a 15x multiple I would value the business at around $0.21 cents for this FY.
25/8/22 Appendix 4E & FY22 Financial Statements
A solid result from AHC, headlined by a 15% growth in revenues despite cycling a tough comp in the 2H21. Management called out the easing of Covid restrictions in key hospital and aged care customers particularly in the 4Q which hopefully bodes well for momentum into FY23. Software revenue grew 18% a solid result but probably below the expectations of management given they are trying to grow software to close to a 50/50 split with hardware revenue (from 14.5% today). That said, management have been clear since the onset of Covid that sales in the segment are complex and benefit from sales access to sites which has been disrupted.
Margins were pressured in FY22, at the gross margin level supply chain issues and chip shortages continue to pose challenges but in the face of that only falling from 53.5% to 52.4% is probably a good result. At the operating level margins took a larger hit with the forecast increase in sales and R&D that was put on hold through Covid disruption. Underlying NPAT increased from $1.5m to $1.7m but benefited from a lower tax rate.
Free cash flow was basically breakeven for the year, down from $1.4m last year. Like many manufacturers the culprit was a build up of inventory, however I will give AHC some leeway here given $3m of the increase was finished goods and the business continues to have a strong order book waiting to be eaten into quickly.
My takeaway from this report is AHC management are flipping the switch from "survive" to "thrive" with Covid disruption now getting further into the rear view mirror. The cost base has been ramped a bit to support a deeper sales team, the former head of Hills Health Solutions (main competitor in APAC) has been poached as the new COO and the order book supports revenue growth over the next couple of years.
Post a valuation or endorse another member's valuation.